INTRODUCTION
Alzheimer's disease (AD) has a distinct pathology with plaques of amyloid-b (Ab) and tangles of hyperphosphorylated tau. Rare autosomal dominant AD cases with mutations of amyloid-b precursor protein (APP) or presenilin (PS1 or PS2) provide proof that Ab pathways can trigger AD (reviewed in Holtzman et al., 2011) . Other APP mutations reduce AD risk (Jonsson et al., 2012) . Biomarker studies of late onset AD have shown that Ab dysregulation, detected by CSF levels or by PET, is the earliest detectable change, consistent with Ab as a trigger (Holtzman et al., 2011) .
The mechanism whereby Ab leads to AD is less clear. Attention has focused on soluble oligomers of Ab (Abo) as causing synaptic malfunction and loss of dendritic spines (Shankar et al., 2008) . In the only reported genome-wide unbiased screen for Abo binding sites, we identified PrP C . Ab binding to PrP C is high affinity and oligomer-specific (Chen et al., 2010; Lauré n et al., 2009 ). In vivo, PrP C is not essential for certain Ab-related phenotypes, but is required for cell death in vitro, for reduced survival of APP/PS1 transgenic lines, for epileptiform discharges, for synapse loss, for serotonin axon degeneration, and for spatial learning and memory deficits (reviewed in Um and Strittmatter, 2013) . Critically, the ability of human AD brain-derived Ab species to suppress synaptic plasticity requires PrP C , and human AD brain contains PrP C -interacting Abo and Ab-PrP C complexes (Barry et al., 2011; Freir et al., 2011; Um et al., 2012; Zou et al., 2011) . Abo-PrP C complexes signal to intracellular Fyn kinase (Larson et al., 2012; Um et al., 2012) . PrP C phenotypes in fish and worms require Fyn (Bizat et al., 2010; Má laga-Trillo et al., 2009) , Fyn regulates Glu receptor traffic and plasticity (Grant et al., 1992; Prybylowski et al., 2005) , and Fyn interacts with tau (Ittner et al., 2010; Roberson et al., 2011) . Both PrP C and Fyn are enriched in the postsynaptic density (PSD), and Abo engagement of PrP C activates Fyn to phosphorylate NMDA receptors (Larson et al., 2012; Um et al., 2012) .
The connection from Abo-PrP C complexes to Fyn cannot be direct, because PrP C is anchored via glycolipid to the plasma membrane whereas Fyn is cytoplasmic. Because both are enriched in PSDs (Collins et al., 2006; Um et al., 2012) , we hypothesized that a transmembrane PSD protein might couple PrP C with Fyn. The PSD proteome includes 81 transmembrane proteins (Collins et al., 2006; Emes et al., 2008) . Here, we screened PSD transmembrane proteins for their ability to couple Abo-PrP C with Fyn. We identified mGluR5 as linking PrP C to Fyn. Activation of neuronal Fyn requires both mGluR5 and PrP C .
Abo-PrP
C can drive mGluR5-dependent calcium mobilization and eEF2 phosphorylation. Antagonists of mGluR5 prevent Abo-induced dendritic spine loss and AD transgene learning and memory deficits. These studies define an Abo-PrP C -mGluR5 complex that leads to impaired neuronal function. 
RESULTS

Screen for PSD Proteins Mediating Abo/PrP
C Signaling
Identifies mGluR5
We considered the 81 known transmembrane PSD proteins as potential mediators (Figures 1A and 1B) . We utilized a cell type in which PrP C and Fyn fail to couple. When PrP C and Fyn are overexpressed in HEK293T cells, Abo does not activate Fyn, as in neurons (Um et al., 2012) . We coexpressed PSD proteins together with PrP C and exposed the HEK cells to Abo prior to assessing Fyn activation by anti-phospho-SFK (Src family kinase) immunoblot ( Figures 1B-1D ). In addition to 56 documented PSD proteins, we included APLP1 and APLP2, due similarity with the PSD protein, APP, and known interaction with PrP C or Abo (Bai et al., 2008; Lauré n et al., 2009; SchmittUlms et al., 2004) . We included the LRRTM family because they organize synapses and modify Ab levels (Linhoff et al., 2009; Majercak et al., 2006) . Of 61 proteins screened, only mGluR1 and mGluR5 increased Fyn activation by >2 SD ( Figures  1C and 1D ). mGluR5 is reported to coimmunoprecipitate and activate Fyn (Heidinger et al., 2002) , to redistribute after Abo (Renner et al., 2010) , to colocalize with Abo (Renner et al., 2010) , and to be required for Abo suppression of LTP (Rammes et al., 2011; Shankar et al., 2008; Wang et al., 2004) .
In the initial screen with Abo, mGluR1 or mGluR5 activity might have been ligand-dependent or independent. Although coexpression of either receptor results in baseline activation of Fyn, only mGluR5 mediates Abo activation ( Figures 1E-1G ). Aboinduced Fyn activation in transfected HEK cells is PrP C dependent, as shown previously for neurons (Um et al., 2012) , because when mGluR5 is expressed without PrP C , no Abo regulation of Fyn occurs. In contrast, basal Fyn activity (without Abo) is independent of PrP C and equal for mGluR1 and mGluR5. Thus, mGluR5 alone has the property of mediating Abo-PrP C activation of Fyn in HEK cells.
Although EphB2 is not a PSD consensus member, we considered EphB2 as a link between Abo and Fyn because it couples with Fyn during development, and because Ab alters EphB2 level (Cissé et al., 2011; Takasu et al., 2002) . In HEK, coexpression of EphB2 and Fyn yields kinase activation (Takasu et al., 2002) , but EphB2 does not mediate Abo signaling ( Figure S1 available online).
We sought to determine whether neuronal mGluR5 is required for Abo-induced Fyn activation. The mGluR5 negative allosteric modulator, MPEP, blocks Abo-induced Fyn activation in HEK cells ( Figure 1E ), so we preincubated cortical neurons with MPEP, or the related MTEP, prior to Abo ( Figures 1H and 1J ). Neither MTEP nor MPEP alters baseline Fyn activity, but both eliminate Abo-induced activation. The mGluR1 antagonist, MPMQ, does not prevent Abo-induced Fyn activation ( Figures  1H and 1J ). We also cultured Grm5 À/À cortical neurons and exposed them to Abo at 21DIV ( Figures 1I and 1J ). Under basal conditions, phospho-Fyn levels were similar to wild-type (WT), but the increase by Abo was eliminated. Thus, mGluR5, as well as PrP C , is required for this Abo signal transduction. If mGluR5 serves as a bridge between PrP C and Fyn, then it is predicted to interact physically with both. We confirmed an association of mGluR5 with Fyn (Heidinger et al., 2002) , and observed no alteration by PrP C or Abo ( Figure S2A ). Both mGluR1 and mGluR5 associate with Fyn, but mGluR8 does not ( Figure S2B ). In HEK293T cells, PrP C immunoprecipitates contain mGluR5, regardless of Abo ( Figure 2C ). Both mGluR1 and mGluR5, but not mGluR8, coimmunoprecipitate with PrP C ( Figure 2D ). We utilized this specificity to examine whether discrete mGluR5 domains are responsible for PrP C interaction ( Figure S2C ). Chimeric proteins containing the N-terminal globular domain from one mGluR fused to the transmembrane domains from another mGluR were coexpressed with PrP C . Each chimera coimmunoprecipitates PrP C less effectively than mGluR5 ( Figure S2D ), suggesting that the PrP C -interacting regions are distributed in the protein. In brain, mGluR5 and PrP C are coenriched in detergent-resistant PSD fractions ( Figure 2E ) (Collins et al., 2006; Um et al., 2012) . To assess association of endogenous proteins extractable with nondenaturing detergent, we covalently crosslinked proteins and then precipitated PrP C . The PrP C immunoprecipitates contain mGluR5, but not mGluR8, NR2B, or GluR1 (Figure 2F ). Immunoprecipitates from Prnp À/À samples do not exhibit mGluR5. Thus, Abo-PrP C , PrP C -mGluR5, and mGluR5-Fyn pairwise physical associations are detectable. Figure 2G ). This staining is reduced by 70% in Grm5 À/À cultures, with the remaining signal similar to Neuron mGluR5 Links Abo-PrP C to Intracellular Signaling the nonspecific low-affinity level observed in nontransfected COS-7 cells (Figures S2E and S2F) . We conclude that mGluR5 contributes significantly as a PrP C partner on the neuronal surface.
Expression of PrP C Plus mGluR5 Supports Abo-Induced
Increase of Intracellular Calcium Activation of Fyn is one consequence of mGluR5 engagement, but activation of the heterotrimeric GTPases, G q /G 11 , with subsequent production of inositol (3,4,5) trisphosphate (IP3) and release of intracellular calcium, is the more prominent pathway (Lü scher and Huber, 2010). We considered whether Abo-PrP C might activate this pathway by injecting RNA for mGluR5 and PrP C into Xenopus laevis oocytes and applying a two-electrode either treated for 1 min with 100 mM Glu to maximally stimulate a response 3 min prior to testing for an Abo response, or not prestimulated with Glu. Alternatively, some oocytes were preincubated with 100 mM BAPTA-AM for 60 min. After these pretreatments, the peak inward current was measured in response to 1.5 mM Abo. Mean ± SEM, n = 6-12 oocytes. **p < 0.005; ANOVA, Tukey post hoc pairwise comparisons. See also Figure S4 .
voltage clamp during bath perfusion of Abo. G protein activation of phospholipase C leads to IP3, calcium release, and opening of an easily detected transmembrane chloride channel in oocytes (Saugstad et al., 1996; Strittmatter et al., 1993) . Glu-induced responses of 3,000 nA peak current at À60 mV are detected in oocytes expressing mGluR1 or mGluR5 ( Figures 3A and 3B ). PrP C does not alter the Glu responses. Bath application of Abo had no effect on conductances for uninjected oocytes, or oocytes expressing mGluR5 alone or PrP C alone ( Figure 3C ). However, in the doubleexpressing mGluR5-PrP C oocytes, Abo produced an inward current of 300-450 nA, 10% of the Glu-induced current. We included only mGluR oocyte batches with Glu responses >500 nA. For preparations with <500 nA responses to Glu, Abo responses of 10% Glu magnitude may be present, but are not prominent. The kinetics and reversal potential for the Aboinduced signal were indistinguishable from that of Glu acting on mGluR5 alone ( Figure 3A and not shown).
The specificity of the Abo-induced current of PrP C -mGluR5 oocytes was examined. Although mGluR1 expression leads to equally strong Glu-induced current (Figures 3A and 3B) , there is no detectable Abo-induced current ( Figures 3A and 3C ). (legend continued on next page) Neuron mGluR5 Links Abo-PrP C to Intracellular Signaling Abo-induced signaling through mGluR5 ( Figure 3C ). The antiPrP C antibody, 6D11, binds to residues 95-105 and prevents Abo interaction (Chung et al., 2010; Lauré n et al., 2009; Um et al., 2012) . Preincubation with 6D11 blocks Abo responses, but not Glu responses, in PrP C -mGluR5 oocytes ( Figures 3B   and 3C ). The Abo-induced response has an EC 50 of 1 mM monomer equivalent, an estimated 10 nM oligomer concentration (Figure 3D) . A characteristic of G protein-mediated responses in Xenopus oocytes is strong desensitization. Maximal Glu stimulation nearly eliminates subsequent responses to Glu for 10-15 min. Consistent with the Abo-PrP C -mGluR5 responses sharing this pathway, pretreatment with Glu eliminates the response to subsequent Abo ( Figure 3E ). In addition, pretreatment with cell permeable BAPTA-AM to chelate intracellular calcium abrogated the Abo-induced signal ( Figure 3E ), as for Glu (Saugstad et al., 1996) . Thus, Abo interaction with a PrP CmGluR5 complex mobilizes calcium stores. Although mGluR5-mediated signaling to Fyn is as robust with Abo-PrP C as with Glu, signaling to calcium mobilization is substantially less effective for Abo-PrP C than with Glu as the mGluR5 ligand, so Abo does not mimic Glu precisely.
Acute Abo-Induced Calcium Signals in Neuronal Culture Require mGluR5 and PrP
C
We considered whether Abo regulates neuronal calcium signaling through mGluR5 directly and acutely. Chronic AboPrP C -Fyn signaling can indirectly alter NMDA receptor (NMDAR) trafficking to modulate NMDA-induced calcium responses (Um et al., 2012) . We used a calcium-sensitive fluorescent dye to assess direct immediate response to Abo in 21 days in vitro (DIV) cortical cultures. In low-density cultures, there is little direct calcium response to Abo under the conditions that modulate NMDAR responses (data not shown; Um et al., 2012) . With microscopic imaging, Abo occasionally induces local calcium transients, but there is no generalization and measurement across a microtiter well does not detect a change (not shown). Higher density cultures exhibit spontaneous synchronized calcium increases ( Figure S3A ) that depend on network connectivity being suppressed by tetrodotoxin (TTX), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), or 2-amino-5-phosphonopentanoic acid (APV) ( Figures S3B and S3C ) (Dravid and Murray, 2004) . Under these conditions, Abo induces an increase of intracellular calcium ( Figure 4A ). Averaging multiple wells smoothes random spontaneous signals ( Figure S3A) , and Abo-induced responses are apparent ( Figure 4A ). This response is oligomer specific; no response is detected with monomeric Ab ( Figure 4C ). In either Grm5 À/À or Prnp À/À neurons, the spontaneous synchronized calcium signals are indistinguishable from WT ( Figures S3D  and S3E ). However, Abo fails to induce a calcium signal in networks lacking either PrP C or mGluR5 ( Figure 4B ).
To assess whether similar responses occur with human autopsy tissue, we utilized Tris-buffered saline (TBS)-soluble extracts from human brain, which we have previously characterized for PrP C -interacting Ab species and for Fyn activation in mouse cultures (Table S1 ) (Um et al., 2012) . In high-density cortical cultures, dialyzed TBS-soluble brain extracts from AD cases generate greater calcium mobilization than do control brain extracts (Figures 4D and 4E ; p < 0.001). Moreover, the level of PrP(23-111)-interacting Ab in human brain samples correlates with the magnitude of the calcium response ( Figure 4F ). Preabsorption with anti-Ab antibody removes PrP C -interacting Ab immunoreactivity ( Figure S3H ) and reduces the calcium response (Figures S3F and S3G) . Preabsorption with PrP-Fc, but not control Fc resin, removes PrP C -interacting species and reduces the calcium response ( Figures 4G and S3I) . Thus, PrP C -interacting Ab species in human AD brain TBS-soluble extracts stimulate calcium signals in high-density neuronal cultures. These responses require network connectivity, and are blocked by TTX, CNQX, or APV ( Figure S4J ). The mGluR5 antagonists, MPEP and MTEP, block the AD brain extract response ( Figure 4I ). In contrast, the mGluR1 antagonist MPMQ does not block the AD extract-induced response ( Figure 4I) . Furthermore, the ability of human AD brain extract to induce a calcium signal is eliminated in Grm5 À/À or Prnp À/À neurons ( Figure 4H ).
We considered the source of calcium for the AD extractinduced signal and its relationship to Fyn. Thapsigargin (TG) pretreatment prevented signaling, consistent with release from endoplasmic reticulum stores ( Figure 4I ). In contrast, TG pretreatment did not prevent Fyn activation ( Figures 4J and 4K) , and inhibition of Fyn with saracatinib did not prevent calcium signaling ( Figure 4I ). Although Fyn and calcium signaling by AD extracts require both PrP C and mGluR5, the two mediators appear pharmacologically separable. Chronic Abo has the potential to desensitize mGluR5 calcium responses. We assessed this in two models: HEK293 cells expressing mGluR5 and PrP C , and low density cultured neurons. HEK-mGluR5 cells respond to Glu with calcium elevation and there is no effect of Abo preincubation ( Figures S4A, S4B , and Figures  S4A, S4C, S4D, and S4F ). This effect requires the Abo-binding PrP(23-111) domain because clones expressing a truncation mutant fail to bind Abo ( Figure S5A ), and show no Abo suppression of Glu-induced calcium (Figures S4E and S4F) . Aboinduced suppression of mGluR5 responses is also observed in neurons. In low density cultures, there are no spontaneous synchronized calcium oscillations, but the mGluR5 agonist, (S)-3,5-dihydroxyphenylglycine (DHPG), results in synchronized oscillations ( Figure S4G ). Pretreatment with Abo nearly eliminates DHPG-induced oscillations in WT neurons (90% inhibition; Figures S4H and S4I) . The Abo suppression of DHPG-induced oscillations is limited to 40% in Prnp À/À cultures ( Figure S4I ).
Multiple mechanisms contribute to mGluR5 desensitization, including protein kinase C, calcium/calmodulin binding, and receptor internalization. We assessed the effect of Abo and the group I mGlu receptor agonist, DHPG, on cell surface mGluR5 levels using biotinylation of live neurons with a cell impermeable reagent ( Figures S4J-S4L) . At 1 hr, DHPG reduces surface mGluR5 by 20%, as described (Choi et al., 2011) . In contrast, Abo treatment generates a PrP C -dependent 25% increase in surface/total mGluR5 ratios ( Figures S4J-S4L ). The increase after Abo addition may reflect ''trapping'' of mGluR5 in relatively immobile complexes (Renner et al., 2010) . Despite this difference between Abo and DHPG in mGluR5 trafficking, Abo treatment suppresses mGluR5 signaling ( Figures S4H and S4I ).
Abo Signals through PrP C and mGluR5 to Protein
Translation Machinery Metabotropic GluRs have effects on protein translation (Lü scher and Huber, 2010), as well as calcium release and Fyn. We examined whether Abo-PrP C -mGluR5 coupling might alter phosphorylation of eukaryotic elongation factor 2 (eEF2). The mGluR5 agonist, DHPG, drives eEF2-56T phosphorylation ( Figure S5A ). Abo treatment has a similar effect on eEF2 phosphorylation (Figures 5A , 5B, and S5A-S5C). Mediation of the Abo effect by mGluR5 is demonstrated by inhibition with MTEP ( Figures S5B  and S5C ). In contrast, the mGluR1 antagonist, MPMQ, does not prevent Abo-induced eEF2 phosphorylation ( Figures S5D  and S5E ). Genetic analysis with Prnp À/À and Grm5 À/À neurons confirms that the Abo effect on eEF2 phosphorylation depends on these proteins ( Figures 5A and 5B ). Abo-induced eEF2 phosphorylation is detected in dendrites, and is absent in Prnp À/À and Grm5 À/À neurons ( Figures 5C and 5D ). The addition of both Abo and DHPG produced no greater eEF2 phosphorylation than either ligand alone, consistent with occlusive action ( Figures  S5F and S5G ). Dendritic translation of Arc is under mGluR5 control, via an eEF2-dependent mechanism (Park et al., 2008) . As predicted from the mGluR5-mediated action of Abo on p-eEF2, dendritic Arc immunoreactivity is elevated after 5 min Abo exposure (Figures 5E and 5F) and Arc immunoblot signal increases in brain slices ( Figures S5H and S5I) .
To extend the AD relevance of these observations, we tested whether human AD extracts generated a similar pattern. Pooled TBS-soluble extracts from AD brain, but not control brain, elevated eEF2 phosphorylation in WT mouse 21 DIV neurons ( Figures 5G and 5H ). This signaling is not observed in Grm5
and Prnp À/À cultures. Thus, Abo-PrP C complexes signal through mGluR5 to modify Fyn activation, calcium levels, and eEF2 phosphorylation. We considered how Abo-induced eEF2 phosphorylation relates to Fyn activation and calcium signaling. Saracatinib suppresses basal p-SFK levels and prevents Abo stimulation of Fyn ( Figure 5I ) and also prevents Abo-induced eEF2 phosphorylation ( Figures 5I and 5K ). Thapsigargin pretreatment prevents AD extract-induced calcium signaling ( Figure 4H ) and also prevents eEF2 phosphorylation ( Figures 5J and 5K) . Thus, eEF2 regulation by Abo requires both Fyn and calcium signaling.
Cellular Effects of Abo Require mGluR5
Time-lapse imaging of myristoyl-GFP expressing neurons (Figure 6A ) has shown that Abo leads to a loss of 10% of dendritic spines over 5 hr by a Prnp-and Fyn-dependent mechanism (Um et al., 2012) . Acute DHPG treatment leads to immature spines, reduced spine volume, and fewer surface AMPA receptors during chemical long-term depression (LTD) (Abu-Elneel et al., 2008; Moult et al., 2006; Vanderklish and Edelman, 2002) , whereas chronic DHPG results in decreased spine density (Shinoda et al., 2010) . We tested whether mGluR5 blockade prevents Abo-induced spine loss. MPEP treatment does not alter baseline spine stability over 5 hr, but prevents Abo-induced loss ( Figures 6A and 6B) . Deletion of mGluR5 also prevents Abo-induced spine loss ( Figures 6A and 6C) . Thus, mGluR5 participates in morphological effects of AboPrP C complexes. The Abo-PrP C -Fyn pathway contributes to short-term lactate dehydrogenase (LDH) release from neurons (Um et al., 2012) . Either addition of the mGluR5 negative allosteric modulator, MTEP, or deletion of the Grm5 gene prevents Abo-induced LDH release ( Figures 6D and 6E ).
mGluR5 Antagonist Reverses Behavioral Deficits in FAD Transgenic Mice
The double transgenic APPswe/PS1DE9 (APP/PS1) mouse exhibits normal behavior through age 6 months, and then progressively loses learning and memory (Gimbel et al., 2010; Jankowsky et al., 2003) . We considered a role for mGluR5. As reported (Lu et al., 1997; Xu et al., 2009) , constitutive mGluR5 deletion impairs performance ( Figure S6 ). Treatment of WT mice with high dose MTEP, 40 mg/kg, impairs alertness and electroencephalogram (EEG) amplitude ( Figure S6 ). Thus, we sought to achieve partial inhibition of mGluR5 with 15 mg/kg MTEP, which does not alter EEG rhythm ( Figure S6 ). First, we treated WT and APP/PS1 mice with vehicle or MTEP and assessed spatial learning in the radial arm water maze ( Figure 7A ). Mice at 9 months age were randomized to blinded treatment with vehicle or MTEP (15 mg/kg, two times a day for 10 days) for 3 days prior to, and then for 7 days throughout memory testing. Learning is impaired in transgenics relative to WT, but is fully recovered with MTEP. There is a significant interaction of genotype and drug (two-way repeated-measures [RM] ANOVA: APP/PS1 3 MTEP interaction, p < 0.01; APP/ PS1, p < 0.01; MTEP, p < 0.01).
Neuron mGluR5 Links Abo-PrP C to Intracellular Signaling
We extended this finding with alternative memory tests and additional cohorts. Without MTEP treatment, APP/PS1 mice at 9 months age are unable to distinguish novel and familiar objects, whereas WT mice exhibit novel object preference (Figure 7B ; p < 0.001 for WT). Exploration of two novel objects is not different between genotypes during acclimation (not shown). MTEP-treated APP/PS1 mice recover a novel object preference ( Figure 7B ; p < 0.001 for both WT and APP/PS1 with MTEP).
A separate cohort of APP/PS1 was tested in the Morris water maze. Without treatment, the APP/PS1 mice show greater latencies to locate a hidden platform relative to WT across learning trials ( Figure 7C ; RM-ANOVA, p < 0.001), and spend less time in the target quadrant during a probe trial for memory 24 hr later ( Figure 7D ; ANOVA p < 0.001). In contrast, MTEPtreated APP/PS1 mice are indistinguishable from untreated WT or MTEP-treated WT mice in learning and memory ( Figures  7C and 7D ), but are different from untreated APP/PS1 (Figures  7C and 7D ; p < 0.001). There is a significant interaction of genotype and drug (two-way RM-ANOVA in Figure 7C for APP/ PS1 3 MTEP interaction, p < 0.001; two-way ANOVA in Figure 7D , p < 0.001).
We also administered MTEP to 3XTg mice expressing mutant APP, PS1, and Tau (Oddo et al., 2003) . At 8-9 months, these mice perform normally in the Morris water maze (not shown), but are impaired in novel object recognition ( Figure 7E ). After randomization to MTEP or vehicle, the 3XTg mice were assessed , n = 3. Mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001; ANOVA, Tukey post hoc pairwise comparisons. (I and J) WT cortical neurons were treated with 0 or 1 mM Abo for 15 min. Indicated samples were treated with 500 nM saracatinib for 1 hr (I) or 100 nM thapsigargin (TG) for 24 hr (J) prior to Abo. Lysates were analyzed by anti-phospho-SFK, anti-Fyn, anti-phospho-eEF2, or anti-eEF2 immunoblot. GAPDH is loading control. (K) Phospho-eEF2 level normalized to eEF2 from three experiments. Mean ± SEM, *p < 0.05; ANOVA, Tukey post hoc pairwise comparisons. See also Figure S5. for novel object recognition ( Figure 7G ). MTEP-treated 3XTg mice show a novel object preference (p < 0.01), but vehicletreated mice do not. Thus, MTEP reverses memory deficits in two transgenic AD mice.
We considered whether improved memory with MTEP is correlated with a reversal of synaptic loss. A separate cohort of WT and APP/PS1 transgenic mice at 10 months age were treated for 10 days with MTEP, 15 mg/kg two times a day. As expected, control APP/PS1 mice exhibit a 25%-30% decrease in area occupied by presynaptic synaptophysin and postsynaptic PSD-95 immunoreactivity in the dentate gyrus ( Figures 8A-8C ). The loss of stained synaptic area was fully rescued by a 10-day course of MTEP ( Figures 8D and 8E ). For WT mice, MTEP did not alter synaptic density. We also assessed synaptic density ultrastructurally, identifying synaptic profiles by the presence of a postsynaptic density and presynaptic vesicles (Figure 8F ). Synapse density in transgenic dentate gyrus increased by 20% with MTEP treatment ( Figure 8G ).
DISCUSSION
This study delineates a direct role for mGluR5 in Abo-related pathophysiology. Of transmembrane PSD proteins, only mGluR5 supports coupling of Abo-PrP C to Fyn activation. Intracellular calcium and protein translation are also linked to Abo-PrP C engagement via mGluR5. An mGluR5 dependence of signaling is observed for TBS-soluble extracts of AD brain as well as synthetic Abo, emphasizing the disease relevance. A coreceptor role for mGluR5 is required for dendritic spine loss and transgenic memory impairment. Together, these findings delineate mGluR5 activation as a critical step in Abo signal transduction with potential for therapeutic intervention.
Dysregulation of mGluR5 Signaling in AD
Several previous studies have indirectly implicated mGluR5 in Abo signaling and in AD. Abo alters mGluR5 trafficking in neurons, with reduced diffusion, clustering, aberrant activation, and neurotoxicity (Renner et al., 2010) . The results here provide a PrP C -based mechanism for these findings and for downstream signaling. Direct coupling of PrPC to mGluR5 has been reported for an unrelated ligand, the laminin gamma-1 chain (Beraldo et al., 2011) . Abo from synthetic, cellular, and human AD brain sources suppresses LTP and enhances LTD. These actions are mimicked by mGluR5 agonists and inhibited by mGluR5 antagonists (Rammes et al., Figure 7 . mGluR5 Antagonist Reverses Learning and Memory Deficits in AD Mouse Models (A) Spatial learning is plotted as the number of errors in finding a hidden platform in a radial arm water maze at age 9 months. Mean ± SEM for vehicle-treated C57BL/6, n = 11; MTEP-treated C57BL/6, n = 12; vehicle-treated APP/PS1, n = 10; MTEP-treated APP/PS1, n = 10. Performance differed across the last 15 swims by genotype and treatment (two-way RM-ANOVA APP/PS1, p < 0.001; MTEP, p < 0.001). There was an interaction between genotype and treatment (two-way RM-ANOVA APP/PS1 3 MTEP p < 0.001). By Tukey post hoc pairwise comparisons across trials, the vehicle-treated APP/PS1 group differed from each of the other groups (p < 0.001), whereas none of the other groups differed from each other (p > 0.05). For indicated trial blocks, the vehicletreated APP/PS1 group differed from each of the other groups (*p < 0.05; **p < 0.01; ***p < 0.001), whereas none of the other groups differed from each other (p > 0.05). (B) Time spent with a novel object for the same mice as (A): vehicle C57BL/6, n = 11; MTEP C57BL/6, n = 12; vehicle APP/PS1, n = 9; MTEP APP/PS1, n = 9. After being acclimated to an object, vehicle APP/PS1 mice showed no preference for a novel object (two-tailed Student's t test p > 0.05). The other three groups showed preference for a novel object (two-tailed Student's t test p < 0.001). (C) Spatial learning is plotted as latency to find a hidden platform in a Morris water maze at age 9 months in a cohort different from (A). Mean ± SEM for untreated (naive) C57BL/6, n = 32; MTEPtreated C57BL/6, n = 13; untreated APP/PS1, n = 38; MTEP-treated APP/PS1, n = 17. Performance differed across the last 16 swims by genotype and treatment (two-way RM-ANOVA for APP/PS1, p < 0.001; for MTEP, p < 0.001). There was an interaction between genotype and treatment (two-way RM-ANOVA, APP/PS1 3 MTEP p < 0.001). By Tukey post hoc pairwise comparisons across trials, the vehicle-treated APP/PS1 group differed from each of the other groups (***p < 0.001), whereas none of the other groups differed from each other (p > 0.05). For specific trial blocks, the untreated APP/PS1 group differed from each of the other groups (*p < 0.05; ***p < 0.001), whereas none of the other groups differed from each other (p > 0.05). (D) Performance during a 60 s probe trial, 24 hr after learning, where time spent in the target quadrant was measured. Random chance is 25%. Mean ± SEM for the groups in (C). Target quadrant time differed by genotype and treatment (two-way ANOVA APP/PS1, p < 0.001; MTEP, p < 0.01). There was an interaction between genotype and treatment (ANOVA, APP/PS1 3 MTEP p < 0.001). By Tukey post hoc, the untreated APP/PS1 group differed from others (p < 0.001), whereas none of the other groups differed from each other (p > 0.05). (E) WT and 3XTg mice of the same genetic background at 8-9 months of age were tested for novel object recognition. WT mice show preference the novel object (two-tailed Student's t test p < 0.05), but 3XTg mice show no preference (p > 0.05). Mean ± SEM. (F) The effect of MTEP administration on object recognition is tested in 3XTg mice at age 8 months. Mean ± SEM for vehicle 3XTg, n = 12; MTEP 3XTg, n = 8. Mice that received MTEP had a significant preference for the novel object (two-tailed Student's t test p < 0.01) whereas vehicle 3XTg mice showed no preference (twotailed Student's t test p > 0.05). See also Figure S6 .
Neuron mGluR5 Links Abo-PrP C to Intracellular Signaling 2011; Shankar et al., 2008; Wang et al., 2004) . In human AD, mGluR ligand binding is decreased in brain relative to controls and the loss is correlated with disease progression (Albasanz et al., 2005) . Proteins titrated by mGluRs, eEF-2, Arc, and p70 S6 kinase are dysregulated in AD brain Li et al., 2005; Wu et al., 2011) .
Signaling Downstream of mGluR5
Canonical mGluR5 signaling couples to G q /G 11 GTPases that activate phospholipase C to produce IP3 and release calcium stores (Lü scher and Huber, 2010) . mGluR5 also modulates plasma membrane potassium, calcium, and transient receptor Neuron mGluR5 Links Abo-PrP C to Intracellular Signaling potential channels. Src family tyrosine kinases, including Fyn, have been implicated in linking to NMDA-R (Heidinger et al., 2002; Nicodemo et al., 2010) . The proline rich tyrosine kinase 2 (Pyk2) participates in Src/Fyn interaction with mGluR signaling (Heidinger et al., 2002; Nicodemo et al., 2010) . The calcium/ calmodulin-dependent eEF2 kinase (eEF2K) is bound to mGluR5 in the basal state, but is released during activation to phosphorylate eEF2 (Lü scher and Huber, 2010). Phospho-eEF2 reduces global translation, but allows increased Arc/Arg3.1 expression (Park et al., 2008) . The Homer family plays a role in mGluR signaling, interacting with receptor and eEF2K (Hu et al., 2010; Lü scher and Huber, 2010; Ronesi et al., 2012) . Homer interactions with SHANK contribute to PSD localization, specific isoforms have roles in homeostatic scaling. We show that Abo-PrP C complexes lead to several mGluR5 outputs. Fyn activation by Abo in cortical neurons requires mGluR5 genetically and pharmacologically. Fyn is implicated in Abo-induced dysregulation of NMDA-R trafficking and activation (Um et al., 2012) . Because Fyn binds directly to Tau (Ittner et al., 2010; Lee et al., 2004) , this may have implications for AD beyond dysregulation of GluRs. The Abo-PrP C -mGluR5 complex also activates phospholipase C, as detected by monitoring calcium-activated chloride channels in oocytes. The ability of Abo or human AD brain TBS-soluble extract to increase calcium in cortical neurons requires mGluR5 and PrP C . The calcium increase in neurons may occur by the IP3 pathway and also by regulation of NMDA-Rs. Fyn activation by Abo-PrP C is as strong as that by Glu, whereas calcium mobilization appears to be an order of magnitude less effective for Abo-PrP C than for Glu. Divergence in Abo-PrP C -mGluR5 signaling requires further study.
Protein translation plays a major role in mGluR5 signaling (Lü scher and Huber, 2010). The phosphorylation of eEF2 is increased by Abo-PrP C as much as by mGluR5 agonist. Therefore dysregulation of translation may contribute to synaptic dysfunction in AD. Arc is one protein target of mGluR5 signaling that is upregulated by Abo acutely. Calcium and Fyn are independent mediators, which appear to cooperate in eEF2 phosphorylation.
We show that mGluR5 antagonists prevent Abo-induced spine loss from hippocampal neurons in vitro and in vivo. Critically, MTEP reverses memory deficits in transgenic AD models. Multiple signaling pathways from Abo-PrP C -mGluR5 complexes are likely to participate. For spine loss in vitro, Fyn is required (Um et al., 2012) , but other mGluR5 signaling components may contribute. Protein translation, calcium release, and Fyn kinase are each known to participate in plasticity, learning, and memory.
Feedback of mGluR5 Signaling on Ab Levels
The mGluR5 pathway may also feedback on APP/Ab metabolism to exacerbate AD. Specifically, mGluR5 agonism elevates Arc, which enhances Ab production by participating in APP and PS1 colocalization within endocytic vesicles . Shared pathways between AD and Fragile X have been reported (Sokol et al., 2011 . Only mGluR5 mediates Abo-induced stimulation of Fyn and calcium signaling in oocytes. Grm5 gene deletion and mGluR5-specific compounds reverse Abo phenotypes, including Fyn activation, neuronal calcium mobilization, eEF2 phosphorylation, spine loss, LDH release, and memory deficits. The mGluR1-specific antagonist, MPMQ, does not block. Thus, mGluR5 appears to be specifically involved in Abo-PrP C action.
PrP C , mGluR5, and Fyn have all been localized to the PSD by subcellular fractionation. For PrP C and Fyn, high-resolution in situ protein localization in brain has not been reported. For mGluR5, imaging confirms a postsynaptic localization and indicates that mGluR5 is dynamically located at the PSD periphery (Lujan et al., 1996) . Dynamic regulation of mGluR5 localization by Abo has been observed (Renner et al., 2010 ).
Short-Term Activation versus Longer-Term Desensitization
Although ionotropic receptors function rapidly, metabotropic receptors are slow and show prominent desensitization. Abo levels are highly unlikely to fluctuate on the time scale of synaptic transmission, so Abo-PrP C complexes may engage mGluR5 and elicit a degree of desensitization that prevents responsiveness to cyclic changes in Glu. Thus, mGluR5 may be dysregulated by acute activation and chronic desensitization.
Alternate Ligands and Accessory Ectodomains for mGluRs Activation of mGluR5 by Abo-PrP C complexes expands the repertoire of metabotropic glutamate receptors. Certain other G protein coupled receptors (GPCRs) respond to more than one ligand, and interact extracellularly with accessory subunits or coreceptors. Melanocortin receptors recognize both melanocortin agonists and Agouti/AgRP antagonists with specificity modified by MRAPs (Breit et al., 2011) . Calcitonin and related receptors have ligand preference altered by transmembrane RAMPs (Hay et al., 2006) . Noncanonical signaling by Hedgehogs and Wnts through Smoothened and Frizzleds to heterotrimeric G proteins depends on ligand interaction with Patched and LRP5/6, respectively (Angers and Moon, 2009; Robbins et al., 2012) . Ectodomain accessory proteins for mGluRs have not been recognized previously, so PrP C is unique. The only previously known endogenous ligand for mGluR5 is Glu, so the action of Abo-PrP C is distinct from precedent. Our findings raise the possibility that mGluR5 may be regulated physiologically by molecules other than Glu.
Targeting mGluR5 for AD Therapy
The delineation of an Abo-PrP C -mGluR5-Fyn pathway provides potential targets for AD intervention. Antibodies that block Abo binding to PrP C reverse memory deficits in transgenic AD mice (Chung et al., 2010) , and we show that a mGluR5 negative allosteric modulator has a similar effect. However, full mGluR5 antagonism may have deleterious effects on neuronal function and impairment of baseline attention (Lü scher and Huber, 2010; Simonyi et al., 2010) . Deficits of contextual fear conditioning and inhibitory learning are observed in the absence of mGluR5 (Xu et al., 2009) , and mGluR5 function may contribute to healthy brain aging (Lee et al., 2005; Mé nard and Quirion, 2012; Nicolle et al., 1999) . Optimal intervention may therefore be designed to prevent Abo-PrP C activation of mGluR5, without modifying Glu activation of mGluR5.
EXPERIMENTAL PROCEDURES
Mouse Strains
All animal studies were conducted with approval of the Yale Institutional Animal Care and Use Committee. The mouse strains have been described previously (Gimbel et al., 2010; Jankowsky et al., 2003; Lu et al., 1997; Oddo et al., 2003) .
Cell Culture and Biochemistry
Standard procedures were utilized, including the assessment of intracellular calcium level in neuronal culture (Um et al., 2012) and voltage clamp recording from X. laevis oocytes Strittmatter et al., 1993) . Freshfrozen postmortem human prefrontal cortex from the brains of AD patients were obtained, as approved by Institutional Review Board collected at New York University and at Yale. Particulate components were removed from TBS homogenates by centrifugation at 100,000 3 g for 30 min.
MTEP Treatment and Memory Testing of Transgenic Mice
Mice were randomized to treatment groups and the experimenter was unaware of treatment status throughout behavioral testing. Procedures for Morris water maze testing have been described (Gimbel et al., 2010) .
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